5AM Ventures
VC Fund
Menlo Park, United States
5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries. 5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.
- Total investments:
- 195
- Last investment:
- Lead investor:
- 37%
- Fund size:
- $450M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries 5AM Ventures invests in
Stages 5AM Ventures invests in
Countries 5AM Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 14 contacts → | |||
Round size
- Series A
- $13M–$70M
- Series B
- $15M–$110M
- Series C
- $14M–$105M
Investment Focus
Industry
- Biotechnology 86 (44%)
- Health Care 56 (29%)
- Therapeutics 39 (20%)
- Medical 23 (12%)
- Pharmaceutical 22 (11%)
Stage
- Series A 61 (31%)
- Series B 49 (25%)
- Series C 18 (9%)
- Post-IPO Equity 13 (7%)
- Seed 9 (5%)
Country
- United States 88 (45%)
- Switzerland 3 (2%)
- United Kingdom 2 (1%)
- Canada 1 (1%)
- Sweden 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
John Diekman
Founder & Managing Partner
|
Founder & Managing Partner | Total investments: 6 | Find email | |
Kush Parmar
Managing Partner
|
Managing Partner | Total investments: 19 | Find email | |
Richard J. Ulevitch
Venture Partner
|
Venture Partner | Total investments: 11 | Find email | |
Scott Rocklage
Founding Partner
|
Founding Partner | Total investments: 13 | Find email | |
Andrew Schwab
Managing Partner
|
Managing Partner | Total investments: 21 | Find email | |
| See all 14 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ALX Oncology
|
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer. It is an independent, private biotechnology company.The founding of Alexo Therapeutics was based upon technology invented by Aaron Ring, K. Christopher Garcia, Kipp Weiskopf, Aron Levin, and Irving Weissman at Stanford University.This discovery involves soluble versions of signal regulatory protein-α (SIRPα) that have been engineered to bind CD47 with significantly greater affinity than natural SIRPα.1. | $150M / Post-IPO Equity / Jan 30, 2026 | |
Mendra
|
Mendra is a biopharmaceutical company that uses AI to accelerate clinical development and commercialization of breakthrough medicines for diseases with high unmet need. | $82M / Series A / Jan 21, 2026 | |
Precede Biosciences
|
Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw. Precede aims to increase drug development success rates and to contribute to a future in which every patient can receive a speedy, minimally invasive diagnosis and therapy tailored to the biology of their condition. | $63.5M / Series B / Jan 12, 2026 | |
ProLynx
|
ProLynx is a biotechnology company that develops proprietary drug-delivery technologies designed to extend the half-life of therapeutic molecules, including peptides, proteins, and small molecules, so they maintain effective levels in the body for controlled periods. The company’s core platform uses β-eliminative linkers that are programmed torelease native drugs from macromolecular carriers (such as circulating polymers or hydrogel microspheres) at predictable rates, enabling sustained release over weeks to months. ProLynx applies this technology to create long-acting therapeutic candidates and partners with pharmaceutical firms and academic researchers to design and test novel drug conjugates. Its pipeline includes extended-duration therapies for metabolic and obesity indications, with a focus on formulations engineered for monthly or quarterly dosing schedules. | $70M / Series A / Dec 11, 2025 | |
Lifordi Immunotherapeutics
|
Lifordi Immunotherapeutics is a biotech company that provides antibody-drug conjugates for autoimmune and inflammatory disorders. | $42M / Venture - Series Unknown / Nov 19, 2025 | |
Ensoma
|
Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As aresult, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited. | $53M / Sep 22, 2025 | |
CAMP4 Therapeutics
|
CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start todisease treatment, significantly reducing the time and risk to bring new medicines to patients. | $50M / Post-IPO Equity / Sep 10, 2025 | |
MapLight Therapeutics
|
MapLight Therapeutics offers a platform designed to discover and develop therapeutics for brain disorders. It combines single-cell transcriptomics and optogenetics to identify novel drug targets and develop effective therapies for brain disorders. | $372.5M / Series D / Jul 28, 2025 | |
Fellow Health
|
Fellow Health provides peer-reviewed, clinical semen analysis solutions that patients can conveniently perform at home. Their services cover full semen analysis, post-vasectomy semen analysis, and cryopreservation. | $24M / Series B / Jul 15, 2025 | |
Renasant Bio
|
Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments. | $54.5M / Seed / Jul 10, 2025 | |
| See all 195 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does 5AM Ventures invest in?
5AM Ventures invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 195 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is 5AM Ventures's check size?
5AM Ventures typically joins rounds of $13M–$70M at Series A, $15M–$110M at Series B and $14M–$105M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds 5AM Ventures participates in.
How do I contact 5AM Ventures?
Public channels for 5AM Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at 5AM Ventures?
The team at 5AM Ventures includes John Diekman (Founder & Managing Partner), Kush Parmar (Managing Partner) and Richard J. Ulevitch (Venture Partner), among 14 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
